The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibit
- PDF / 1,076,030 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 12 Downloads / 184 Views
LETTER TO THE EDITOR
Open Access
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors Ying Jin1,2†, Dong-Liang Chen1,2†, Feng Wang1,2†, Chao-pin Yang1,3, Xu-Xian Chen1,4, Jin-qi You1,3, Jin-Sheng Huang1,4, Yang Shao5,6, Dong-Qin Zhu5, Yu-Ming Ouyang5, Hui-Yan Luo1,2, Zhi-Qiang Wang1,2, Feng-Hua Wang1,2, Yu-Hong Li1,2, Rui-Hua Xu1,2* and Dong-Sheng Zhang1,2*
Abstract A more common and noninvasive predicting biomarker for programmed cell death 1 (PD-1) antibody remains to be explored. We assessed 46 patients with advanced gastric cancer who received PD-1 antibody immunotherapy and 425-genes next-generation sequencing (NGS) testing. Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher response rate than those who did not (7.3 months vs 3.6 months, p = 0.0011; 53.3% vs 13.3%, p = 0.06). The median PFS of patients with undetectable and detectable post-treatment circulating tumor DNA (ctDNA) was 7.4 months vs. 4.9 months (p = 0.025). Mutation status of TGFBR2, RHOA, and PREX2 in baseline ctDNA influenced the PFS of immunotherapy (p < 0.05). Patients with alterations in CEBPA, FGFR4, MET or KMT2B (p = 0.09) gene had greater likelihood of immune-related adverse events (irAEs). ctDNA can serve as a potential biomarker of the response to immunotherapy in advanced gastric cancers, and its potential role in predicting irAEs worth further exploration. Keywords: Circulating tumor DNA, Immune checkpoint inhibitors, Gastrointestinal cancer, Advanced, Biomarkers Gastric cancer is the fifth most common malignant tumor and the third leading cause of cancer-related death worldwide [1]. The immune Checkpoint Inhibitors (ICIs), mainly the antibodies against PD-1, have been recommended as a palliative therapy option for selective patients with metastatic gastric adenocarcinoma, with predictive biomarkers including the microsatellite instability (MSI) status, Combined Positive Score (CPS) of PD-L1 expression, and Epstein-Barr virus (EBV) status of tumor [2, 3]. Our team have identified tumor mutation burden (TMB) as a biomarker for OS benefit in chemo-refractory * Correspondence: [email protected]; [email protected] † Ying Jin, Dong-Liang Chen and Feng Wang contributed equally to this work. 1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China Full list of author information is available at the end of the article
gastric cancer treated with PD-1 antibody [4]. However, in real-world practice, patients with advanced gastric cancer may lack fresh tissue and have to obtained tissue samples from invasive re-biopsy. ctDNA has been reported to have utility in identifying genetic alterations and predicting the prognosis, identifying resistance of target therapy, and monitoring relapse or progression of gastric cancer [5]. What’s more, ctDN
Data Loading...
